Home > Press release

 

 

ARCHIVE PRESS RELEASE
Chiesi Group mid-year financial results demonstrate strong growth for 2023
03 Agosto 2023
Chiesi's Sustainability Report 2022: a year of tangible achievements for patients, communities, and the planet
27 Luglio 2023
Alessandro Chiesi appointed Chair of the Chiesi Group
Maria Paola Chiesi becomes the Vice Chair
07 Luglio 2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23 Giugno 2023
Chiesi Global Rare Diseases Announces FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
10 Maggio 2023
Chiesi Global Rare Diseases Announces European Commission (EC) Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05 Maggio 2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12 Aprile 2023
2022 for Chiesi: The Group’s international growth continues
05 Aprile 2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01 Marzo 2023
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
07 Marzo 2023
© 2025 CHIESI Farmaceutici S.p.A.
VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE


follow us on: